Last CNY45.03 CNY
Change Today +0.11 / 0.24%
Volume 2.2M
As of 2:00 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

walvax biotechnology co-a (300142) Snapshot

Open
CNY44.73
Previous Close
CNY44.92
Day High
CNY46.40
Day Low
CNY44.65
52 Week High
10/13/14 - CNY48.82
52 Week Low
07/24/14 - CNY30.32
Market Cap
10.5B
Average Volume 10 Days
2.0M
EPS TTM
CNY-0.38
Shares Outstanding
234.0M
EX-Date
--
P/E TM
--
Dividend
CNY0.05
Dividend Yield
0.09%
Current Stock Chart for WALVAX BIOTECHNOLOGY CO-A (300142)

Related News

No related news articles were found.

walvax biotechnology co-a (300142) Related Businessweek News

No Related Businessweek News Found

walvax biotechnology co-a (300142) Details

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, is engaged in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It provides bio-medicines, such as vaccines, blood products, and others. The company offers Group A and C meningococcal polysaccharide vaccine for children and adults over the age of 2 years to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis, etc. It also provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. The company was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.

Founded in 2001

walvax biotechnology co-a (300142) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

walvax biotechnology co-a (300142) Key Developments

Walvax Biotechnology Co.,Ltd, Special/Extraordinary Shareholders Meeting, Nov 28, 2014

Walvax Biotechnology Co.,Ltd, Special/Extraordinary Shareholders Meeting, Nov 28, 2014., at 10:00 China Standard Time. Agenda: To consider the acquisition of 100% equity stake in a company.

Walvax Biotechnology Co.,Ltd to Report Q3, 2014 Results on Oct 27, 2014

Walvax Biotechnology Co.,Ltd announced that they will report Q3, 2014 results on Oct 27, 2014

Walvax Biotechnology Co.,Ltd, Special/Extraordinary Shareholders Meeting, Oct 27, 2014

Walvax Biotechnology Co.,Ltd, Special/Extraordinary Shareholders Meeting, Oct 27, 2014., at 10:00 China Standard Time. Agenda: To transfer of 46% equity in a company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300142:CH CNY45.03 CNY +0.11

300142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300142.
View Industry Companies
 

Industry Analysis

300142

Industry Average

Valuation 300142 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WALVAX BIOTECHNOLOGY CO-A, please visit www.walvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.